Sahr Yazdani
YOU?
Author Swipe
View article: PIKfyve, expressed by CD11c-positive cells, controls tumor immunity
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity Open
Cancer treatment continues to shift from utilizing traditional therapies to targeted ones, such as protein kinase inhibitors and immunotherapy. Mobilizing dendritic cells (DC) and other myeloid cells with antigen presenting and cancer cell…
View article: Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330] Open
View article: PIKfyve controls dendritic cell function and tumor immunity
PIKfyve controls dendritic cell function and tumor immunity Open
The modern armamentarium for cancer treatment includes immunotherapy and targeted therapy, such as protein kinase inhibitors. However, the mechanisms that allow cancer-targeting drugs to effectively mobilize dendritic cells (DCs) and affec…
View article: Case report: Two unexpected cases of DGUOK-related mitochondrial DNA depletion syndrome presenting with hyperinsulinemic hypoglycemia
Case report: Two unexpected cases of DGUOK-related mitochondrial DNA depletion syndrome presenting with hyperinsulinemic hypoglycemia Open
Timely diagnosis of persistent neonatal hypoglycemia is critical to prevent neurological sequelae, but diagnosis is complicated by the heterogenicity of the causes. We discuss two cases at separate institutions in which clinical management…
View article: Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma
Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma Open